Global /Australia /Healthcare /Drug Manufacturers - General /NUZ

Neurizon Therapeutics Ltd.

NUZ

• ASX: NUZ • Delayed

0.0820AUD -3.5%

0.0578 USD

As of 6 June 2026, Neurizon Therapeutics Ltd. has a market cap of $45.01M USD, ranking #31350 globally and #787 in Australia. It ranks #2835 in the Healthcare sector, and #990 in the Drug Manufacturers - General industry.

Global Rank

31350

Country Rank

787

Sector Rank

2835

Industry Rank

990

Key Stats

Market Cap

$45.01MUSD

63.08M AUD

Enterprise Value

$39.98MUSD

56.75M AUD

Revenue (TTM)

$4.27MUSD

5.98M AUD

EBITDA (TTM)

-$10.47MUSD

-14.87M AUD

Net Income (TTM)

-$10.6MUSD

-14.85M AUD

EBITDA Margin

-249%

Profit Margin

-248%

PS Ratio

10.5

PB Ratio

7.6

Company Profile

Country (HQ)

Australia

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Michael Thurn open_in_new

Employees

Founded

2000

Website

neurizon.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-3.5%	2.4%	6.3%	-4.5%	-32%	-25%	-26%	-15%	-13%

News

Markets

Exchange	Ticker	Price	Quotes
Australian Securities Exchange (ASX) MIC: XASX PRIMARY	NUZ Neurizon Therapeutics Ltd ISIN: AU0000357261 Shares Out.: Shares Outstanding: 753.983M¹ Shares Float: 695.963M² TV: TradingView: ASX: NUZ SA: Stock Analysis: ASX: NUZ YF: Yahoo Finance: NUZ.AX GF: Google Finance: ASX: NUZ BA: Barron's: NUZ MS: Morningstar: XASX: NUZ	0.0820 AUD	TV: TradingView: ASX: NUZ SA: Stock Analysis: ASX: NUZ YF: Yahoo Finance: NUZ.AX GF: Google Finance: ASX: NUZ BA: Barron's: NUZ MS: Morningstar: XASX: NUZ

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Neurizon Therapeutics Ltd.

Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Similar Companies

Industry: Drug Manufacturers - General (Australia)

Name	Market Cap (USD) diff.	PE	Country
Sigma Healthcare Ltd. ASX: SIG	$22.82B 31.98B AUD 51K%	52.3	Australia
PYC Therapeutics Ltd. ASX: PYC	$926.22M 1.3B AUD 2K%	-	Australia
Racura Oncology Ltd. ASX: RAC	$346.24M 485.18M AUD 669%	-	Australia
Clinuvel Pharmaceuticals Ltd. ASX: CUV	$335.4M 469.99M AUD 645%	14.5	Australia
Starpharma Holdings Ltd. ASX: SPL	$216.39M 303.23M AUD 381%	-	Australia
Mayne Pharma Group Ltd. ASX: MYX	$166.4M 233.18M AUD 270%	-	Australia

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 2M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 1M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 801K%	97.4	United States
Roche Holding AG SIX: RO	$324.68B 256.25B CHF 721K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.43B 215.59B GBP 643K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$277.35B 218.9B CHF 616K%	20.5	Switzerland

chevron_leftBack